Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis

Patients aged between 18 and 70 with acute aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) positive optic neuritis, irrespective of prior using of corticosteroids in this episode of disease, are chosen by the physician. Patients will then be randomized to receive high dose of intravenous corticosteroids combined with plasma exchange (PE), or merely high dose of intravenous corticosteroids followed subsequent taper. The main outcome of visual acuity and OCT parameters will be compared at baseline, one, three and six months after treatments, and other assessments will also be recorded and compared. This will allow for determination on whether additional PE plays a role in better prognosis in acute AQP4-IgG positive optic neuritis.

Definition:

This will be a parallel designed, open-labeled, randomized add-on comparison study between 1) intravenous high dose corticosteroids combined with plasma exchange (PE) and 2) merely intravenous high dose corticosteroids followed subsequent taper of the improvement of optic nerve function in acute aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) positive optic neuritis. The investigators will compare assessments at baseline with those at one, three and six months post treatments.

Patients:

Subjects will be recruited from in-patients who were diagnosed as AQP4-IgG positive optic neuritis in Neuro-Ophthalmology Department in People's Liberation of Army General Hospital (PLAGH) in Beijing, China.

Eligible participants should have inaugural or recurrent unilateral or bilateral optic neuritis attack(s) within 30 days from the first symptom onset. Only affected eyes with VA less than 20/200 at baseline will be included in the study. All of the participants have to have positive serum AQP4-IgG. Enrollment will be allowed irrespective of whether a previous diagnosis of neuromyelitis optica spectrum disorders (NMOSD) was made.

Participants will be randomly assigned (1:1) to exclusively intravenous corticosteroid (CS group) or sequential intravenous corticosteroid and PE( CS and PE group) .

All participants will receive intravenous corticosteroid (1g of methylprednisolone per day for 3\~5days, and subsequent taper). The treatment will be started as soon as the participant is admitted to the hospital. The participants in CS and PE group will receive add-on five consecutive PE every other day performed in the ward.

Primary and secondary endpoints:

The primary endpoint will be the value of visual acuity (VA ) at end of follow-up (6 months) in the affected eyes. VA was assessed separately for each eye using Snellen's test chart at baseline, one, three and six months, and was converted to LogMAR for calculation of the mean visual acuity. If the patient has a relapse during the follow-up, the last VA recorded before the relapse will be the final VA outcome of the patient.

Optical Coherence Tomography (OCT) parameters assessed at months 6 will be another primary endpoint. OCT will be performed with spectrum domain OCT (SD-OCT) (Carl Zeiss 5000). Peripapillary retinal nerve fiber layer (pRNFL), macular retinal thickness and macular Ganglion Cell Layer + inner plexiform layer (mGCIPL) will be measured by one skilled technician at the condition of dilated pupil to avoid bias of measurement. Parameters above will be recorded thereafter.

Secondary endpoints will study the numbers of relapses during the follow-up of 6 months, optic nerve conduction velocity measured by Flash Visual Evoked Potential (FVEP) at the end of follow-up (6 months). FVEP will be recorded by visual electro-physiology equipment (Roland RETI-Port/Scan 21). The same technician will perform all the assessments for all the patients to avoid bias of measurement. A final latency assessment was analysed at study end.

Titer of serum AQP4-IgG within 1 month after their attack and six months after treatment will be recorded. Orbital MRI will be assessed and compared if it is necessary.

Security indexes:

Safety assessment at screening，baseline，one , three, and six month are: physical examination and vital signs including blood pressure (BP), heart rate (HR). Hematology and blood chemistry will be assessed as well. blood routine test, coagulation Test, and serum electrolyte will be tested during the PE treatment and followed up at one, three and six months. Allergies during PE treatment will be recorded by doctors. Patients experiencing severe adverse events would be remove from the treatment arm. However, patients with slight or medium adverse events should complete their PE treatment unless they require to quit.

Sample size:

The estimated mean VA outcome of AQP4-IgG positive optic neuritis 6 months after its attack is expected to be about 1.4 (LogMAR) with its standard deviation (SD) around 1.3 (LogMAR), based on 2 observation reports. Another observational study found that mean VA outcome after PE combined corticosteroid treated AQP4-IgG positive optic neuritis was 0.75 (LogMAR). The investigators assume that to achieve 80% power at 5% significance level, using a parallel design, the sample size needs to be 64 cases per group and 128 in all. By accounting for 10% patients potentially withdrawing consent or being lost to follow-up over the course of the study, the final sample size will be increased to 71 cases per arm and 142 patients in all.

Planned Statistical Analysis:

The primary analysis will be intention-to-treat. The outcome of the superiority clinical trial will be assessed based on a two-sided 95% confidence interval around the mean VA and OCT outcome, showing a credible range for true difference between merely corticosteroid and corticosteroid combined PE treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 to 70 years old
2. Serum AQP4-IgG positive optic neuritis
3. Patients must have their VA less than 20/200
4. Course of disease is less than 1 month
5. Patients must provide written informed consent

Exclusion Criteria:

1. Females who are pregnancy
2. Patients who are severely allergic to plasma or albumin
3. Patients who have systemic disease and can not accept PE
4. Patients with a tendency to thrombus